Multiple sclerosis (MS) and neuromyelitis optica (NMO) are common autoimmune demyelinating disorders of the central nervous system. The exact etiology of each remains unclear. CYP7A1 was reported to be associated with NMO in Korean patients, but this is yet to be confirmed in other populations. In this study, we used Sanger sequencing to detect SNPs in the promoter region of CYP7A1 in a population consisting of unrelated patients and controls from the Han Chinese population (129 MS; 89 NMO; 325 controls). Two known SNPs, −204A>C (rs3808607) and −469T>C (rs3824260), and a novel SNP (−208G>C) were identified in the 5'-UTR of CYP7A1. The −204A>C was in complete linkage with −469T>C and both were associated with NMO but not with MS. Results suggest that the CYP7A1 allele was associated with NMO. NMO and MS have different genetic risk factors. This further supports the emerging evidence that MS and NMO are distinct disorders.
INTRODUCTION
Multiple sclerosis (MS) is the most common autoimmune demyelinating disorder of the central nervous system (CNS). The exact etiology remains unclear although genes, the environment and interactions thereof play significant roles [1, 2] . The diagnosis of MS depends on clinical and paraclinical features including magnetic resonance imaging (MRI) [3] . No specific diagnostic biomarker has been identified to date [3] . Similarly, neuromyelitis optica (NMO)
is an inflammatory demyelinating disease of the CNS previously distinguished from MS by having severe attacks of optic neuritis and transverse myelitis with longitudinally extensive lesions on spinal MRI but with a brain MRI often characterized by very few lesions [4, 5] . Morbidity for NMO greatly exceeds that for MS [6] . Despite advances in diagnostic criteria [3, 7] , MS and NMO have overlapping clinical manifestations, such as age of onset, female predilection, optic neuritis, and spinal syndrome. Thus, in the clinical setting, it can be diffi cult to differentiate them, especially if the patient is anti-aquaporin-4 (AQP4) antibody negative. Diagnostic accuracy is critical with respect to therapies that can infl uence the prognosis [4, 5, 8] .
MS is relatively frequent in Caucasians and relatively infrequent in Asians. However, NMO is relatively common in Asians but rare in Caucasians. We hypothesized that this difference may result from genetic factors [9, 10] . To date, little is known about the genetic factors that may distinguish NMO from MS. The genetic component of MS susceptibility is complex and has been studied for several decades. Although several genes have been implicated, the greatest impact is from the human leukocyte antigen (HLA) DRB1*1501 (6p21.1-21.3) genotype [11] . However, the genetics of NMO susceptibility remain largely unknown. Recently, the interleukin 17 (IL-17) and HLA-DPB1*0501 allele were reported to be associated with Asian NMO patients positive for the NMO-IgG antibody [12] [13] [14] [15] [16] [17] , and there was a suggestion that the emergence of anti-AQP4 antibody is reinforced by the presence of the HLA-DPB*0501 and IL-17 allele [13, 15] . In addition, CYP7A1 was reported to be associated with Korean NMO patients [18] .
Cholesterol 7 alpha-hydroxylase, which is encoded by CYP7A1, is a rate-limiting enzyme for cholesterol catabolism and bile-acid synthesis involved in cholesterol homeostasis [19] [20] [21] [22] . The human CYP7A1 gene, consisting of 6 exons, is located on chromosome 8 (8q11−q12) [23] .
Here, we assessed the association between the SNPs in the promoter region of CYP7A1 and Han Chinese patients diagnosed with either MS or NMO compared to controls.
METHODS

Subjects
The study protocol was approved by the Ethics Committee from southern China were recruited from Huashan Hospital.
MS patients were diagnosed according to the 2005
McDonald Criteria [24] and NMO patients were diagnosed according to the revised 2006 Wingerchuk Criteria [25] .
Medical history, demographic information and diagnosis were independently reviewed by two senior neurologists.
Serology included autoimmune antibodies (ANA, ENA, dsDNA, ANCA, and AMA); complement and NMO−IgG were tested. All samples from MS and NMO patients were tested for IgG−Index but this was not done for controls.
Genomic DNA was extracted from peripheral EDTA blood with a TIANamp Blood DNA kit (Tiangen Biotech, Beijing)
for all patients and controls.
Genotyping of SNPs in the Promoter of CYP7A1 Using Sanger Sequencing
The primers (forward: 5'-GGATGTTAGGTGAGTAACATG-3'
and reverse: 5'-AGCATGCTGCTATAGCAATCC-3') were designed to amplify the 5'-untranslated region (UTR) and intron-exon boundary of exon 1 of CYP7A1. The PCR product (662 bp) was generated using a GeneAmp PCR system 9600 (Applied Biosystems, Foster City, CA).
Amplified products were purified and direct sequencing of DNA performed using an ABI 3730 Automated DNA Sequencer (Applied Biosystems) [26] . Sequences were compared with the genomic DNA sequence of CYP7A1
(NCBI Sequence Viewer NM_000780.3), and nucleotide changes were numbered corresponding to their position in CYP7A1.
Statistical Analysis
The Hardy−Weinberg equilibrium of the SNPs rs3808607 and rs3824260 in the promoter region of CYP7A1 was determined for all participants using the χ 2 test (df = 1).
Genotype distributions and allele frequencies in MS and
NMO patients were compared to controls, also by the χ 2 test. Unconditional logistic regression was used to calculate the odds ratios (ORs) and 95% confidence intervals (95% CIs) as estimates of relative risk for the single-locus genotypes, with adjustment for age and sex. All statistical analyses were performed using STATA software (version 9.2; College Station, TX). The criterion for a significant difference was P <0.05.
RESULTS
We recruited 129 unrelated MS patients, 89 unrelated NMO Table S1 . Anti-AQP4 antibody was tested in 41 NMO patients, and 20 (48.8%) were positive, a lower proportion than has been reported in previous studies.
Consistent with previous reports, there were no antibodypositive MS patients [27] .
Two 
DISCUSSION
Similar to MS, NMO is a common autoimmune demyelinating disorder of the CNS. Although genes, the environment and their interactions play signifi cant roles in the pathogenesis of the disease, no clear etiology has been established yet [10] . As reported previously, the genetic component of MS susceptibility is complex and has been studied for several decades, and NMO is presumably a polygenetic condition, like MS. However, the genetics of NMO susceptibility remain largely unknown. It is important to fi nd a risk gene that may be helpful in revealing the etiology of NMO.
Recently, CYP7A1 was reported to be associated with Korean NMO patients [18] . Cholesterol 7 alphahydroxylase, which is encoded by CYP7A1, is a member of the cytochrome P450 superfamily of enzymes and is the fi rst rate-limiting enzyme in the bile-acid synthesis pathway.
A previous study identified several cell-specific enhancer elements between −432 and −220 in the promoter region of CYP7A1, including the functional binding sites for hepatocyte nuclear factor-3 (HNF-3), HNF-4, and a ubiquitous transcription factor, the activity of which is controlled in part by HNF-3 [28] . Deletion of the segment from −213 to −91 reduces the promoter activity by 40% [22] , and this defect in CYP7A1 may play a pathogenic role in cholesterol gallstone disease [29] . The activity of CYP7A1 may also be affected by −204A>C and −469T>C, by infl uencing its transcription rate [22] .
In the present study, we found that these two polymorphisms are tightly linked. The CC genotype of −204A>C but not −469T>C confers a higher risk for gallbladder cancer (GBC) in a North Indian population [30] , indicating that these two SNPs are not tightly linked to GBC. Possible explanations include (1) the allele distribution may vary among different ethnic groups, or (2) methodological differences. Restriction fragment length polymorphism was used in the GBC study [30] and the more sensitive direct DNA sequencing in the present study.
Association between −204A>C and NMO patients was found in the present study, replicating the Korean fi ndings [18] . but there is no evidence for this [31, 32] . Therefore, further exploration of this gene region for other candidates that play an important role in the susceptibility/pathogenesis of NMO is warranted.
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